📢 Published on June 13, 2024
Researchers from Stanford University have published the results of a study in Nature Medicine that examined the effectiveness of the treatment combining Botensilimab and Balstilimab in patients with metastatic colon cancer whose cancer cells are of the MSS type.
The study included 148 patients, and the results were impressive:
- 61% of the patients responded, meaning their disease was stabilized and some metastases even shrank.
- During the analysis conducted after 10.3 months, those who responded continued to respond.
Here is the link to the publication:
🔗 https://www.nature.com/articles/s41591-024-03083-
Why is this study a breakthrough?
- Because among this patient population, MSS, there were no structured studies, but mainly those with MSI-H were examined.
- This is the first time we have seen a structured study with an effective immunotherapy combination in patients who have already undergone several lines of treatment and are MSS, with a very impressive success rate.
🔍 What is MSS, MSI-H?
These are proteins whose role is to repair errors in the DNA sequence that occur during DNA replication in the cell division process.
A deficiency (MSI-H) in one of these proteins causes the cell to accumulate DNA changes – mutations, which can lead to cancer development. No deficiency is MSS.
In the pathological institute, it is possible to check whether there is a deficiency.
🔍 What is the connection between these proteins and colon cancer patients?
In about 15-20% of colon tumors, there is a deficiency in one of these proteins.
Remember, we are here for you.
Identifying and supporting obtaining of innovative drugs and advanced treatments from around the world for metastatic and stage 4 cancer patients.
Share the post, it might help someone you know!
